drugset / Trial / NCT06577558
Efficacy and Safety of SR1375 in Adult Patients With CAP
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.
Timeline
- Start
- 2024-09-10
- Primary completion
- 2025-10-15
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SR1375 | Unknown | 0.3 mg | Oral |
| Subject | SR1375 | Unknown | 1 mg | Oral |
| Subject | SR1375 | Unknown | 3 mg | Oral |